BioStock: Annexin’s CMO on study results and participation in ARVO

Biotech company Annexin Pharmaceuticals earlier announced encouraging first results in one of two studies evaluating the candidate ANXV in retinal vein occlusion. In the imaging study SIGHT, data from the first patient show that the candidate binds to the desired area and target molecule. The results provide support for the continued development of ANXV as a treatment for the disease. CMO/CSO and Co-founder Anna Frostegård tells BioStock more about the results and the ARVO congress that the company recently participated in.

Read the interview with Annexin Pharmaceuticals' CMO/CFO and Co-founder Anna Frostegård here:

https://www.biostock.se/en/2023/05/annexins-cmo-on-study-results-and-participation-in-arvo/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/